Physician profile
Michael W Bittenbender
NPI 1730171083
$17,051.38
in general payments reported to CMS, 2019-2025
50 companies · $2,749 in 2025
The $2,749 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $2,387 · 2021: $2,897 · 2022: $2,304 · 2023: $2,484 · 2024: $2,352 · 2025: $2,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,547 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,546.83 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,675.22 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,065.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,211.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,146.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $981.07 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.07 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $893.82 | 2019-2025 | Trintellix |
| Amgen INC. | $856.14 | 2019-2025 | Evenity, Otezla, Prolia |
| Lilly USA, LLC | $574.19 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $571.23 | 2021-2025 | |
| Allergan, INC. | $503.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $464.99 | 2019-2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $419.90 | 2019-2023 | |
| Antares Pharma, INC. | $293.61 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $282.86 | 2019-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $277.16 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $265.51 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $258.17 | 2019-2023 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $242.77 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.80 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $179.03 | 2019-2021 | |
| Astellas Pharma US INC | $178.23 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.82 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $136.74 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $124.95 | 2019-2023 | Livalo, Seglentis |
| Axsome Therapeutics, INC. | $111.15 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $103.50 | 2019-2025 | Rexulti |
| Mylan Specialty L.P. | $97.65 | 2020-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $96.95 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $69.05 | 2021-2022 | |
| Daiichi Sankyo INC. | $61.31 | 2019-2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $57.59 | 2023-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $54.73 | 2022 | |
| Sumitomo Pharma America, INC. | $54.38 | 2023 | Gemtesa |
| Abbott Laboratories | $46.22 | 2019-2025 | Freestyle Libre 3 |
| Tolmar, INC. | $43.19 | 2023-2025 | Jatenzo |
| Boston Scientific Corporation | $41.33 | 2022-2025 | Watchman Flx |
| Atricure, INC. | $38.45 | 2024 | |
| Eisai INC. | $38.19 | 2020 | |
| Viatris Specialty LLC | $22.57 | 2025 | Yupelri |
| Pulmonx Corporation | $22.11 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Vyera Pharmaceuticals, LLC | $20.37 | 2022 | |
| Agios Pharmaceuticals, INC. | $19.84 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.64 | 2020 | |
| Corcept Therapeutics | $17.94 | 2025 | Korlym |
| Arbor Pharmaceuticals, INC. | $17.52 | 2021 | |
| Lifescan, INC. | $16.90 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.01 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $15.21 | 2019 | |
| Organon LLC | $10.76 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bittenbender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.